Phase 2 N=154 Safety and Efficacy of IDA for Onchocerciasis
Onchocerciasis
Primary: Rates of Severe Adverse Events (SAEs) Across Study Arms — 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=12 Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
Loiasis
Primary: The Peak % of Baseline Eosinophil Count Measured During the First 7 Days Post-treatment. — 196; 165 percentage of baseline — p=0.68
Phase 3 N=164 Moxidectin for LF, Cote d'Ivoire (DOLF)
Lymphatic Filariasis
Primary: Clearance of Microfilaremia (IA vs. MoxA) — 8; 18; 24; 27 Participants
Phase 2 N=8 Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Loiasis
Primary: Peak Eosinophil Count Post-treatment — 61; 245.6 percent of baseline eosinophil count — p=0.028
Phase 4 N=41 Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
Loiasis
Primary: Cross-reactive Antigenemia — 12 Participants
Phase 3 N=12,979 Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
Onchocerciasis
Primary: Incidence and Severity of Treatment Emergent Adverse Events — 346; 79; 1199; 288 participants
N/A N=17,108 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Lymphatic Filariasis · Soil Transmitted Helminth Infections
Primary: Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood — 54; 36; 146; 46 Participants
Phase 4 N=128 Partnership for Rapid Elimination of Trachoma
Trachoma
Primary: Community Prevalence of Trachoma and Ocular C. Trachomatis (CT) Infection at Baseline — 30.7; 30.3; 31.1; 30.5 community
Phase 4 N=104 Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon
Scabies · Households
Primary: Number of Participants With Clinical Cure — 20; 33 Participants
Phase 2 N=40 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
Lymphatic Filariasis
Primary: Microfilarial Counts at 1 Year — 0; 0; 0 MF/ML — p=<0.2
N/A N=72 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
Lymphatic Filariasis
Primary: Dermatology Life Quality Index (DLQI) Domain Scores — 3; 0; 1; 0 units on a scale
Phase 3 N=255 Efficacy and Safety of MOX/ALB Co-administration
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) of Moxidectin/Albendazole Combination Therapy Compared to Albendazole Monotherapy Against T. Trichiura — 15.3; 13.4 percentage of participants (%)
Phase 3 N=223 Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Strongyloides Stercoralis Infection
Primary: Observed Cure Rate Against Strongyloides Stercoralis — 73.3; 89.7; 84.4; 82.8 percentage of participants
Phase 3 N=1,673 Efficacy and Safety of IVM/ALB Co-administration
Trichuriasis
Primary: Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured) — 24; 32; 16; 140 Participants
Phase 2 N=260 Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) Against T. Trichiura — 17.5; 50.0; 83.3; 84.6 percentage of participants cured (%)
Phase 2 N=176 Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients
Trichuris Infection · Helminthiasis
Primary: Cure Rate — 1; 31; 6; 40 Participants
Phase 3 N=356,912 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
Helminthiasis · Filariasis
Primary: Comparison of Arms - Benin — 322; 748; 11; 11 Participants
Phase 4 N=1,291 Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Scabies · Yaws · Impetigo
Primary: Impetigo Prevalence at 12 Months — 79; 66; 20; 12 Cases of impetigo
Phase 3 N=174 Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
Trypanosomiasis, African · Sleeping Sickness · Trypanosomiasis; Gambian
Primary: Percentage of Participants Whose Treatment Outcome at Month 18 is a Success — 93.1 percentage of participants
Phase 3 N=332 Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Strongyloides Stercoralis Infection
Primary: Cure Rate Against Strongyloides Stercoralis — 94.8; 99.4 percentage of participants
Phase 3 N=118 Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands
Scabies · Head Lice
Primary: Number of Participants With Headlice — 3 Participants
Phase 2 N=700 Albendazole Dose Finding and Pharmacokinetics in Children and Adults
Trichuriasis · Hookworm Infections
Primary: Cure Rate Against T. Trichiura and Hookworm Infections — 4; 2; 4; 5 Participants
N/A N=87 Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil
Hookworm Infection
Primary: Size of Wheal Diameter at Site of Skin Test Application, Measured 15 Minutes After Injection — 3.5 cm
Phase 3 N=208 Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense
Trypanosomiasis, African · Gambiense Trypanosomiasis · Sleeping Sickness
Primary: Percentage of Participants With Late-stage HAT Whose Treatment Outcome Was a Success at Month 18 According to Adapted World Health Organization (WHO) Criteria — 95.2…
Phase 3 N=224 Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) Against T. Trichiura — 69.4; 16.2; 11.8 percentage of participants cured (%)
Phase 1 N=36 A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
Onchocerciasis
Primary: Area Under the Plasma Concentration Versus Time Curve of Moxidectin. — 2680; 2230; 3310; 1880 (hr*ng/mL)/mg
Phase 4 N=1,347 Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
Trachoma · Chlamydia Trachomatis
Primary: Infection With Chlamydia Trachomatis Diagnosed by Use of NAATs [Nucleic Acid Amplification Test] — 57; 42; 5; 3 Participants
Phase 3 N=911 Clinical Endpoint Study of Ivermectin 0.5% Lotion
Head Lice
Primary: Percentage of Index Participants Who Were Considered a Treatment Success: PP Population — 90.9; 89.0 percentage of participants
Phase 4 N=1,452 Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia
Trichiasis
Primary: Recurrent Trichiasis in Tetracycline and Azithromycin Groups — 45; 62 Participants — p=.047
Phase 2 N=22 Dose-finding Study of Moxidectin for Treatment of Scabies
Scabies
Primary: Mortality Rate for Adult Scabies Mites — 2; 6; 8; 14 Adult mites